Hydroxy-Safflower Yellow A Mitigates Vascular Remodeling in Rat Pulmonary Arterial Hypertension

References

• Barlow A, Barlow B, Koyfman A, et al. Pulmonary arterial hypertension in the emergency department: a focus on medication management. Am J Emerg Med. 2021;47:101–108. doi:10.1016/j.ajem.2021.03.072
   PubMed Web of Science ®Google Scholar
• Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61.
   Web of Science ®Google Scholar
• Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53.
   Web of Science ®Google Scholar
• Zhao C, Le X, Li M, et al. Inhibition of Hsp110-STAT3 interaction in endothelial cells alleviates vascular remodeling in hypoxic pulmonary arterial Hypertension model. Respir Res. 2023;24(1):289. doi:10.1186/s12931-023-02600-5
   PubMed Web of Science ®Google Scholar
• Luna-López R, Ruiz Martín A, Escribano Subías P. Pulmonary arterial hypertension. Med Clin. 2022;158(12):622–629. doi:10.1016/j.medcli.2022.01.003
   PubMed Web of Science ®Google Scholar
• Tuder RM. Pulmonary vascular remodeling in pulmonary hypertension. Cell Tissue Res. 2017;367(3):643–649. doi:10.1007/s00441-016-2539-y
   PubMed Web of Science ®Google Scholar
• Hajra A, Safiriyu I, Balasubramanian P, et al. Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension. Curr Probl Cardiol. 2023;48:101236. doi:10.1016/j.cpcardiol.2022.101236
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Guignabert C, et al. Treatment of pulmonary arterial hypertension: recent progress and a look to the future. Lancet Respir Med. 2023;11(9):804–819. doi:10.1016/S2213-2600(23)00264-3
   PubMed Web of Science ®Google Scholar
• Gurevich S, Prins KW. The evolving role of interventional cardiology in the treatment of pulmonary hypertension. Catheter Cardiovasc Interv. 2021;97(4):E446–e453. doi:10.1002/ccd.29146
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903. doi:10.1056/NEJMoa012212
   PubMed Web of Science ®Google Scholar
• Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–2157. doi:10.1056/NEJMoa050010
   PubMed Web of Science ®Google Scholar
• Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006;129(3):683–688. doi:10.1378/chest.129.3.683
   PubMed Web of Science ®Google Scholar
• Auth R, Klinger JR. Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs. 2023;32(11):1025–1042. doi:10.1080/13543784.2023.2274439
   PubMedGoogle Scholar
• Yan K, Wang X, Zhu H, et al. Safflower yellow improves insulin sensitivity in high-fat diet-induced obese mice by promoting peroxisome proliferator-activated receptor-γ2 expression in subcutaneous adipose tissue. J Diabetes Investig. 2020;11(6):1457–1469. doi:10.1111/jdi.13285
   PubMed Web of Science ®Google Scholar
• Kong D, Xia W, Zhang Z, et al. Safflower yellow injection combined with conventional therapy in treating unstable angina pectoris: a meta-analysis. J Tradit Chin Med. 2013;33(5):553–561. doi:10.1016/S0254-6272(14)60021-2
   PubMed Web of Science ®Google Scholar
• Zhang Q, Peng JH, Zhang XN. A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome. Chin J Integr Med. 2005;11:222–225. doi:10.1007/BF02836509
   PubMedGoogle Scholar
• Sun X, Wei X, Qu S, et al. Hydroxysafflor Yellow A suppresses thrombin generation and inflammatory responses following focal cerebral ischemia-reperfusion in rats. Bioorg Med Chem Lett. 2010;20:4120–4124. doi:10.1016/j.bmcl.2010.05.076
   PubMed Web of Science ®Google Scholar
• Chen J, Pan M, Wang J, et al. Hydroxysafflor yellow A protects against colitis in mice by suppressing pyroptosis via inhibiting HK1/NLRP3/GSDMD and modulating gut microbiota. Toxicol Appl Pharmacol. 2023;467:116494. doi:10.1016/j.taap.2023.116494
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang L, Jin M, Zang BX. Hydroxysafflor yellow A alleviates early inflammatory response of bleomycin-induced mice lung injury. Biol Pharm Bull. 2012;35:515–522. doi:10.1248/bpb.35.515
   PubMed Web of Science ®Google Scholar
• Bai Y, Lu P, Han C, et al. Hydroxysafflor yellow A (HSYA) from flowers of Carthamus tinctorius L. and its vasodilatation effects on pulmonary artery. Molecules. 2012;17:14918–14927. doi:10.3390/molecules171214918
   PubMed Web of Science ®Google Scholar
• Jingshan Z, Qianyu G, Shaohong L, et al. Hydroxysafflor yellow A inhibits rat vascular smooth muscle cells proliferation possibly via blocking signal transduction of MEK-ERK1/2. Zhonghua Xin Xue Guan Bing Za Zhi. 2015;43:728–731.
   PubMedGoogle Scholar
• Li T, Han D, Li Z, et al. Hydroxysafflor Yellow A Phytosomes Administered via Intervaginal Space Injection Ameliorate Pulmonary Fibrosis in Mice. Pharmaceuticals;2022. 15. doi:10.3390/ph16010015
   Web of Science ®Google Scholar
• Li L, Dong P, Hou C, et al. Hydroxysafflor yellow A (HSYA) attenuates hypoxic pulmonary arterial remodelling and reverses right ventricular hypertrophy in rats. J Ethnopharmacol. 2016;186:224–233. doi:10.1016/j.jep.2016.04.004
   PubMed Web of Science ®Google Scholar
• Han X, Zhang Y, Zhou Z, et al. Hydroxysafflor yellow A improves established monocrotaline-induced pulmonary arterial hypertension in rats. J Int Med Res. 2016;44(3):569–584. doi:10.1177/0300060515597931
   PubMed Web of Science ®Google Scholar
• Zhang R, Zhu X, Bai H, Ning K. Network Pharmacology Databases for Traditional Chinese Medicine: review and Assessment. Front Pharmacol. 2019;10:123. doi:10.3389/fphar.2019.00123
   PubMed Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682–690. doi:10.1038/nchembio.118
   PubMed Web of Science ®Google Scholar
• Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards Suite: from Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016;54(1):1.30.1–1.30.33. doi:10.1002/cpbi.5
   PubMedGoogle Scholar
• Oliveros JC (2007-2015) Venny. An interactive tool for comparing lists with Venn’s diagrams. Available from: https://bioinfogp.cnb.csic.es/tools/venny/index.html. Accessed February 15, 2024.
   Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–d613. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: new Docking Methods, Expanded Force Field, and Python Bindings. J Chem Inf Model. 2021;61(8):3891–3898. doi:10.1021/acs.jcim.1c00203
   PubMed Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461. doi:10.1002/jcc.21334
   PubMed Web of Science ®Google Scholar
• Wang L, Zhu W, Sun R, et al. Network Pharmacology Prediction and Molecular Docking-Based Strategy to Discover the Potential Pharmacological Mechanism of Wen-Yu-Jin against Pulmonary Fibrosis in a Mouse Model. Evid Based Complement Alternat Med. 2022;2022:7753508. doi:10.1155/2022/7753508
   PubMed Web of Science ®Google Scholar
• Sakao S, Tatsumi K. Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities. Int J Cardiol. 2011;147(1):4–12. doi:10.1016/j.ijcard.2010.07.003
   PubMed Web of Science ®Google Scholar
• Kadioglu O, Chan A, Cong Ling Qiu A, et al. Artemisinin Derivatives Target Topoisomerase 1 and Cause DNA Damage in Silico and in Vitro. Front Pharmacol. 2017;8:711. doi:10.3389/fphar.2017.00711
   PubMed Web of Science ®Google Scholar
• Feng J, Guo J, Yan J, et al. Luhong Formula and Hydroxysafflor yellow A protect cardiomyocytes by inhibiting autophagy. Phytomedicine. 2023;110:154636. doi:10.1016/j.phymed.2022.154636
   PubMed Web of Science ®Google Scholar
• Yoshida S, Minematsu N, Chubachi S, et al. Annexin V decreases PS-mediated macrophage efferocytosis and deteriorates elastase-induced pulmonary emphysema in mice. Am J Physiol Lung Cell Mol Physiol. 2012;303(10):L852–60. doi:10.1152/ajplung.00066.2012
   PubMedGoogle Scholar
• Krahling S, Callahan MK, Williamson P, Schlegel RA. Exposure of phosphatidylserine is a general feature in the phagocytosis of apoptotic lymphocytes by macrophages. Cell Death Differ. 1999;6(2):183–189. doi:10.1038/sj.cdd.4400473
   PubMed Web of Science ®Google Scholar
• Luo C, Ji X, Fan J, et al. Annexin A5 promotes macrophage activation and contributes to pulmonary fibrosis induced by silica particles. Toxicol Ind Health. 2016;32(9):1628–1638. doi:10.1177/0748233715572744
   PubMed Web of Science ®Google Scholar
• De Kock L, Freson K. The (Patho)Biology of SRC Kinase in Platelets and Megakaryocytes. Medicina. 2020;56. doi:10.3390/medicina56020056
   Google Scholar
• Liu P, Gu Y, Luo J, et al. Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1 signaling pathway. Exp Cell Res. 2019;380(1):36–46. doi:10.1016/j.yexcr.2019.02.022
   PubMed Web of Science ®Google Scholar
• Norton CE, Sheak JR, Yan S, et al. Augmented Pulmonary Vasoconstrictor Reactivity after Chronic Hypoxia Requires Src Kinase and Epidermal Growth Factor Receptor Signaling. Am J Respir Cell Mol Biol. 2020;62(1):61–73. doi:10.1165/rcmb.2018-0106OC
   PubMed Web of Science ®Google Scholar
• Jacobs W, van de Veerdonk MC, Trip P, et al. The Right Ventricle Explains Sex Differences in Survival in Idiopathic Pulmonary Arterial Hypertension. Chest. 2014;145(6):1230–1236. doi:10.1378/chest.13-1291
   PubMed Web of Science ®Google Scholar
• Lahm T, Tuder RM, Petrache I. Progress in solving the sex hormone paradox in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2014;307(1):L7–L26. doi:10.1152/ajplung.00337.2013
   PubMed Web of Science ®Google Scholar
• Morris H, Denver N, Gaw R, et al. Sex Differences in Pulmonary Hypertension. Clin Chest Med. 2021;42(1):217–228. doi:10.1016/j.ccm.2020.10.005
   PubMed Web of Science ®Google Scholar
• Hu WP, Xie L, Hao SY, et al. Protective effects of progesterone on pulmonary artery smooth muscle cells stimulated with Interleukin 6 via blocking the shuttling and transcriptional function of STAT3. Int Immunopharmacol. 2022;102:108379. doi:10.1016/j.intimp.2021.108379
   PubMed Web of Science ®Google Scholar
• Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59:21–26. doi:10.1016/j.ijrobp.2003.11.041
   PubMed Web of Science ®Google Scholar
• Norton CE, Broughton BR, Jernigan NL, et al. Enhanced depolarization-induced pulmonary vasoconstriction following chronic hypoxia requires EGFR-dependent activation of NAD(P)H oxidase 2. Antioxid Redox Signal. 2013;18:1777–1788. doi:10.1089/ars.2012.4836
   PubMed Web of Science ®Google Scholar
• Dahal BK, Cornitescu T, Tretyn A, et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med. 2010;181(2):158–167. doi:10.1164/rccm.200811-1682OC
   PubMed Web of Science ®Google Scholar
• Merklinger SL, Jones PL, Martinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation. 2005;112(3):423–431. doi:10.1161/CIRCULATIONAHA.105.540542
   PubMed Web of Science ®Google Scholar
• Toby IT, Chicoine LG, Cui H, et al. Hypoxia-induced proliferation of human pulmonary microvascular endothelial cells depends on epidermal growth factor receptor tyrosine kinase activation. Am J Physiol Lung Cell Mol Physiol. 2010;298:L600–6. doi:10.1152/ajplung.00122.2009
   PubMed Web of Science ®Google Scholar
• Tseng V, Sutliff RL, Hart CM. Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension. Antioxid Redox Signal. 2019;31(12):874–897. doi:10.1089/ars.2018.7695
   PubMed Web of Science ®Google Scholar
• Khandekar MJ, Banks AS, Laznik-Bogoslavski D, et al. Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. Proc Natl Acad Sci U S A. 2018;115(3):561–566. doi:10.1073/pnas.1717776115
   PubMed Web of Science ®Google Scholar
• Cai G, Liu J, Wang M, et al. Mutual promotion of FGF21 and PPARγ attenuates hypoxia-induced pulmonary hypertension. Exp Biol Med. 2019;244(3):252–261. doi:10.1177/1535370219828692
   Web of Science ®Google Scholar
• Liu J, Cai G, Li M, et al. Fibroblast growth factor 21 attenuates hypoxia-induced pulmonary hypertension by upregulating PPARγ expression and suppressing inflammatory cytokine levels. Biochem Biophys Res Commun. 2018;504(2):478–484. doi:10.1016/j.bbrc.2018.09.004
   PubMed Web of Science ®Google Scholar
• Wright AF, Ewart MA, Mair K, et al. Oestrogen receptor alpha in pulmonary hypertension. Cardiovasc Res. 2015;106:206–216. doi:10.1093/cvr/cvv106
   PubMed Web of Science ®Google Scholar
• Frump AL, Goss KN, Vayl A, et al. Estradiol improves right ventricular function in rats with severe angioproliferative pulmonary hypertension: effects of endogenous and exogenous sex hormones. Am J Physiol Lung Cell Mol Physiol. 2015;308(9):L873–90. doi:10.1152/ajplung.00006.2015
   PubMed Web of Science ®Google Scholar
• Matori H, Umar S, Nadadur RD, et al. Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats. Hypertension. 2012;60(2):425–430. doi:10.1161/HYPERTENSIONAHA.112.191445
   PubMed Web of Science ®Google Scholar
• Umar S, Partow-Navid R, Ruffenach G, et al. Severe pulmonary hypertension in aging female apolipoprotein E-deficient mice is rescued by estrogen replacement therapy. Biol Sex Differ. 2017;8:9. doi:10.1186/s13293-017-0129-7
   PubMed Web of Science ®Google Scholar
• Lahm T, Albrecht M, Fisher AJ, et al. 17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med. 2012;185:965–980. doi:10.1164/rccm.201107-1293OC
   PubMed Web of Science ®Google Scholar
• Lahm T, Crisostomo PR, Markel TA, et al. Selective estrogen receptor-alpha and estrogen receptor-beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism. Am J Physiol Regul Integr Comp Physiol. 2008;295:R1486–93. doi:10.1152/ajpregu.90667.2008
   PubMed Web of Science ®Google Scholar